Cryptococcosis Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)
DelveInsight’s, “Cryptococcosis Pipeline Insight 2023” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in the Cryptococcosis pipeline landscape. It covers the Cryptococcosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cryptococcosis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Cryptococcosis Pipeline Report
- DelveInsight’s Cryptococcosis pipeline report depicts a robust space with 4+ active players working to develop 4+ pipeline therapies for Cryptococcosis treatment.
- The leading companies working in the Cryptococcosis Market include Matinas BioPharma, Mycovia Pharmaceuticals, Aparna Biosciences, FUJIFILM Toyama Chemical, TGV Therapeutics, Amplyx Pharmaceuticals, and others.
- Promising Cryptococcosis Pipeline Therapies in the various stages of development include Voriconazole, ITCZ-IV, Posaconazole, Fluconazole, Amphotericin B, Flucytosine, and others.
- March 2023: Matinas BioPharma Nanotechnologies Inc. announced a study of Phase 1 & 2 clinical trials for MAT2203 and Amphotericin B. This study is designed as two sequential trials. The first is a phase I open label trial to evaluate the safety and tolerability of MAT2203. The maximal tolerated and non-toxic daily dose,will then be moved forward into a multi-day safety trial. The Phase II trial will investigate toxicity and early fungicidal activity (EFA) of MAT2203 with flucytosine.
- April 2023: Makerere University announced a study of Phase 2 & 3 clinical trials for Fluconazole. This will be a randomized controlled trial of asymptomatic (Cryptococcal Antigen test)CrAg positive persons in Uganda. Patients will be randomized to receive preemptive treatment with 1 dose of liposomal amphotericin (10mg/kg) in addition to standard of care fluconazole therapy.
Request a sample and discover the recent advances in Cryptococcosis Treatment Drugs @ Cryptococcosis Pipeline Report
In the Cryptococcosis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cryptococcosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Cryptococcosis Overview
Cryptococcosis is caused by a fungus known as Cryptococcosis neoformans. The infection may be spread to humans through contact with pigeon droppings or unwashed raw fruit. Contact with an infected individual may also spread the infection. Individuals with disorders characterized by lowered immunity (for instance, HIV infection) are at high risk for contracting these infections.
Find out more about Cryptococcosis Therapeutics Assessment @ Cryptococcosis Preclinical and Discovery Stage Products
Cryptococcosis Emerging Drugs Profile
- MAT 2203: Matinas BioPharma
Cryptococcosis Pipeline Therapeutics Assessment
There are approx. 4+ key companies which are developing the Cryptococcosis therapies. The Cryptococcosis companies which have their Cryptococcosis drug candidates in the most advanced stage, i.e. phase II include, Matinas BioPharma.
DelveInsight’s Cryptococcosis pipeline report covers around 4+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Cryptococcosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
Cryptococcosis Pipeline Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Learn more about the emerging Cryptococcosis Pipeline Therapies @ Cryptococcosis Clinical Trials Assessment
Scope of the Cryptococcosis Pipeline Report
- Coverage- Global
- Cryptococcosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Cryptococcosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Cryptococcosis Companies- Matinas BioPharma, Mycovia Pharmaceuticals, Aparna Biosciences, FUJIFILM Toyama Chemical, TGV Therapeutics, Amplyx Pharmaceuticals, and others.
- Cryptococcosis Pipeline Therapies- Voriconazole, ITCZ-IV, Posaconazole, Fluconazole, Amphotericin B, Flucytosine, and others.
Dive deep into rich insights for new drugs for Cryptococcosis Treatment, Visit @ Cryptococcosis Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Cryptococcosis: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Cryptococcosis – DelveInsight’s Analytical Perspective
- Mid Stage Products (Phase II)
- MAT 2203: Matinas BioPharma
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- MYC 053: TGV Therapeutics
- Drug profiles in the detailed report…..
- Inactive Products
- Cryptococcosis Key Companies
- Cryptococcosis Key Products
- Cryptococcosis- Unmet Needs
- Cryptococcosis- Market Drivers and Barriers
- Cryptococcosis- Future Perspectives and Conclusion
- Cryptococcosis Analyst Views
- Cryptococcosis Key Companies
- Appendix
For further information on the Cryptococcosis Pipeline therapeutics, reach out to Cryptococcosis Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting
){kind=link}